Navigation Links
Many Phase 3 Cancer Drug Trials Yield Effective Medicines
Date:3/24/2008

Between a third and a half of these studies bring real clinical improvements, researchers say

MONDAY, March 24 (HealthDay News) -- From 25 percent to 50 percent of new cancer treatments tested in phase 3 randomized clinical trials are eventually found to be effective, say American researchers who analyzed data from 624 phase 3 trials involving more than 216,000 patients.

The trials were all conducted by U.S. National Cancer Institute-funded cooperative groups since 1955.

Dr. Benjamin Djulbegovic, of the H. Lee Moffitt Cancer Center and Research Institute at the University of South Florida in Tampa, and colleagues found that 30 percent of the trials had statistically significant results.

In 80 percent of those trials, new treatments were found to be superior to established treatments. The risk-benefit ratio favored new treatments in 41 percent of comparisons, and favored standard treatments in 59 percent of comparisons.

"The real effects of new treatments compared with standard treatments in terms of patient outcomes such as survival is best measured by quantitative pooling of data," the study authors wrote. "When done this way, new treatments are, on average, found to be slightly superior to standard treatments, with a five percent relative reduction in the death rate. This, of course, should not be understood as the average effects of new discoveries being equally spread among all patients."

The researchers also found that breakthrough therapies were discovered in 15 percent of the trials and, in two percent of cases, the breakthroughs reduced the death rate by more than 50 percent.

The study was published in the March 24 issue of the journal Archives of Internal Medicine. Two of the study co-authors received consulting fees and grant support from drug makers Sanofi-Aventis, AMGEN, and Eli Lilly and Company.

"In conclusion, society has received a good return on its investment in the cooperative oncology group system," which funds the trials, the study authors wrote. "The public can expect that about 25 percent to 50 percent of new cancer treatments that reach the stage of assessment in clinical trials will prove to be successful. This pattern of successes has become more consistent over time. However, our results also indicate that the absolute number of discoveries might be improved if the proportion of inconclusive trials is reduced."

Cancer is the second leading cause of death in the United States. Over the years, there have been continuous improvements made in survival and other outcomes, in large part due to the introduction of new treatments tested in clinical trials, according to background information in the study.

More information

The U.S. National Cancer Institute has more about cancer clinical trials.



-- Robert Preidt



SOURCE: JAMA/Archives journals, news release, March 24, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Cancer treatments in phase 3 trials successful up to half of the time
2. Cardiome Announces Positive Interim Phase 2b Results for Oral Vernakalant and Engages Merrill Lynch as Strategic Advisor
3. MGH initiates phase I diabetes trial
4. Enrollment completed in 2 pivotal phase III studies of the investigational cancer drug vandetanib
5. Labopharm Initiates Phase III Clinical Trial for Twice-Daily Formulation of Tramadol-Acetaminophen
6. Akela Pharma initiates its first abuse deterrent opioid Phase I clinical trial
7. Affinium Pharmaceuticals, Ltd. Announces Initiation of a Phase I Clinical Trial for AFN-1252, its Novel Anti-staphylococcal Antibiotic
8. CEL-SCI CORPORATION Announces Results of 2008 Annual Meeting of Shareholders and Provides Update on Ground-breaking Activities Regarding Construction of Manufacturing Facility for Pivotal Phase III Cancer Trial
9. Bradmer announces Phase II results published in newly diagnosed glioblastoma which demonstrate improved survival and support upcoming Phase III study
10. Hyperion Therapeutics Announces Enrollment of First Patient in Phase 2 Clinical Trial in Patients With Hepatic Encephalopathy
11. Positive results from phase 1 clinical trials of cuprindro
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Many Phase 3 Cancer Drug Trials Yield Effective Medicines
(Date:1/19/2017)... IL (PRWEB) , ... January 19, 2017 , ... ... N.A., announced it recently provided a new $11,250,000 senior credit facility to Sunrise, ... new MB credit facility were used to facilitate a recapitalization of MedPro led ...
(Date:1/19/2017)... Huntington Beach, CA (PRWEB) , ... January 19, ... ... for Oral Health, is now offering treatments for patients with sleep apnea and ... far-reaching consequences for dental and physical health. Dr. Rassouli provides personalized care to ...
(Date:1/19/2017)... , ... January 19, 2017 , ... Sam & Associates ... to commercial and residential clients in the California Bay Area, is launching a charity ... in the region. , Heart disease is the primary killer of adult men and ...
(Date:1/19/2017)... ... ... St. Catherine’s Village announced that a limited number of rooms have become available ... grounds of the St. Catherine’s Village campus in Madison, Mississippi that accommodates 120 residents ... Mississippi for the second year in a row by readers of the Clarion-Ledger. , ...
(Date:1/19/2017)... ... January 18, 2017 , ... The CHP suggests that California ... rain storm by slowing down and increasing the space between themselves and other vehicles, ... based car accident attorney Raymond R. Hassanlou notes that, rain or shine, drivers should ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... January 19, 2017 The global  pacemaker market  is expected ... Grand View Research, Inc. The heightening prevalence of cardiac conditions coupled with the ... Pacemaker globally. In addition, technological enhancements in these devices are supporting the expansion ... ... Grand View Research Logo ...
(Date:1/19/2017)... , Jan. 18, 2017   Synthetic Biologics, ... company developing therapeutics designed to preserve the microbiome ... today confirmed plans to initiate a Phase 2b/3 ... reformulation of lovastatin lactone designed to reduce methane ... in the gut to treat the underlying cause ...
(Date:1/18/2017)... -- Aprima Medical Software, a leading provider of innovative ... revenue cycle management (RCM) solutions for medical practices, ... Healthcare Data Solutions (HDS) of Coral Cables, FL. ... full support for HDS,s customers, which include approximately ... states. Financial terms were not disclosed. ...
Breaking Medicine Technology: